Biopharmaceuticals Contract Manufacturing

Biopharmaceuticals Contract Manufacturing Market by Product (Biologics, Biosimilar), Source (Mammalian, Non-Mammalian), Services, Scale of Operation, Therapeutic Applications - Global Forecast 2024-2030

360iResearch Analyst
Want to know more about the biopharmaceuticals contract manufacturing market or any specific requirement? Ketan helps you find what you're looking for.
This free PDF includes market data points, ranging from trend analysis to market estimates & forecasts. See for yourself.

[186 Pages Report] The Biopharmaceuticals Contract Manufacturing Market size was estimated at USD 18.27 billion in 2023 and expected to reach USD 19.16 billion in 2024, at a CAGR 5.14% to reach USD 25.95 billion by 2030.

Biopharmaceuticals Contract Manufacturing Market
To learn more about this report, request a free PDF copy

Biopharmaceutical contract manufacturing is the outsourcing of biopharmaceutical production processes to third-party manufacturers. These specialized entities possess the expertise, equipment, and facilities required to manufacture biopharmaceutical products, which include vaccines, monoclonal antibodies, recombinant proteins, and other biologically derived pharmaceuticals. This collaborative approach enables biopharmaceutical companies to leverage external capabilities and resources to enhance scalability, reduce costs, and accelerate the time to market for new therapies. The biopharmaceutical contract manufacturing market is driven by an increasing pipeline of biologic drugs, rising demand for biosimilars, and the complexity of biologic drug production processes. The need for specialized manufacturing capabilities, stringent regulatory requirements, and the desire to reduce costs and time-to-market push pharmaceutical companies toward outsourcing. However, the high price of setting up a production facility for biopharmaceuticals may hinder market growth. Nevertheless, rising investments in biopharmaceutical R&D and manufacturing, coupled with a growing emphasis on personalized medicine globally, are expected to create potential opportunities for market growth.

Biopharmaceuticals Contract Manufacturing Market - Global Forecast 2024-2030
To learn more about this report, request a free PDF copy
Services: Proliferating utilization of analytical and QC studies critical for meeting regulatory standards

Analytical and quality control (QC) studies are vital in ensuring the safety, efficacy, and quality of biopharmaceutical products. This service encompasses a range of activities, including method development, validation, stability testing, and batch release testing. These studies are critical for meeting regulatory standards and ensuring manufactured products meet specifications. Fill and finish operations are a crucial stage in the manufacturing process of biopharmaceuticals, involving the aseptic filling of the final drug into its container, followed by finishing tasks such as labeling and packaging. This process requires precision and high standards of cleanliness to maintain the sterility and integrity of the product, making it a critical component in the contract manufacturing of biopharmaceuticals. Packaging services for biopharmaceuticals go beyond simply enclosing the product. They involve designing and developing packaging systems that protect the product from environmental factors, ensure its stability during storage and transport, and comply with regulatory requirements. Sophisticated packaging solutions also provide patient convenience and support compliance with treatment regimens. Process development is a critical service in biopharmaceuticals contract manufacturing, focusing on designing, optimizing, and scaling up production processes to ensure cost-effectiveness, efficiency, and compliance with quality standards. This includes the development of cell culture processes, purification processes, and integration process analytics to ensure the process is robust and sustainable for commercial manufacturing. Downstream processing involves recovering and purifying biological substances produced during upstream processing. This phase is critical for removing impurities and concentrating the product. Techniques involved in downstream processes include chromatography, filtration, and precipitation, all of which are essential for ensuring the purity and quality of the final biopharmaceutical product. Upstream Processing refers to the initial phase of biopharmaceutical manufacturing, which involves cultivating cells in bioreactors under controlled conditions to produce the desired biological substance. This service requires expertise in cell line development, media preparation, and bioreactor operation, forming the foundation for producing biologically active substances that can be further processed and finalized as therapeutic products.

Scale of Operation: Evolving commercial scale of operation for biopharmaceuticals contract manufacturing

The clinical scale of operation in biopharmaceutical contract manufacturing refers to producing small to medium batches of biopharmaceutical products intended for clinical trials. This scale prioritizes flexibility, precision, and compliance with regulatory standards to assure the efficacy and safety of products under investigation. The production processes are designed to accommodate the evolving requirements of clinical development stages, facilitating the transition from preclinical studies to Phase I, II, and III clinical trials. At this scale, the focus is on adaptability and the ability to scale up processes as the product moves closer to commercialization. Contract manufacturing organizations (CMOs) offering services at the clinical scale are equipped with cutting-edge technology and expertise to handle complex biologics, including monoclonal antibodies, recombinant proteins, and gene therapies, ensuring that products meet the stringent quality standards required for clinical research. The commercial scale of operation in biopharmaceutical contract manufacturing involves large-scale production intended for the mass market following regulatory approval. This scale focuses on efficiency, cost-effectiveness, and the ability to meet the high demand for approved biopharmaceutical products. Commercial-scale manufacturing requires a significant investment in infrastructure, technology, and quality control systems to assure consistent product quality and compliance with global regulatory requirements. Contract manufacturing organizations serving at the commercial scale have the capabilities to optimize production processes, manage supply chains effectively, and ensure the timely delivery of large quantities of biopharmaceuticals. This scale of operation is characterized by a continuous commitment to operational excellence, process optimization, and adherence to Good Manufacturing Practices (GMP) to meet the stringent standards of the biopharmaceutical industry and address the health needs of populations globally.

Regional Insights

The Americas represent a significant market for biopharmaceuticals contract manufacturing, attributed to its advanced technological infrastructure, robust regulatory framework, and significant investments in biotech research. Recent initiatives focus on precision medicine and biologics, with numerous patents filed in bioprocessing and genetic engineering technologies. In addition, the emphasis on research in monoclonal antibodies and vaccines has attracted global contract manufacturing organizations (CMOs) to invest in the country. The biopharmaceutical contract manufacturing sector in Asia Pacific is booming, owing to the upgrading of manufacturing capabilities and enhancement of biologics production, with considerable investments in cell therapy and recombinant protein drugs. Furthermore, significant patents in bioreactor technologies and regenerative medicine and the focus on biosimilars and vaccines for domestic and international markets propel investments and collaborations, offering numerous opportunities for CMOs. The European Union exhibits growth in the biopharmaceuticals contract manufacturing market, supported by its advanced healthcare infrastructure and strong regulatory standards. Recent trends indicate a surge in biologics production and a growing interest in personalized medicines and cell therapies. Despite being nascent, the Middle East is gradually advancing in biopharmaceutical contract manufacturing, with investments focusing on vaccine production and biosimilars to address the rising healthcare needs. Africa's biopharmaceutical contract manufacturing is developing due to the region's focus on establishing local manufacturing capabilities to reduce dependency on imported drugs, emphasizing vaccines and common therapeutics.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Biopharmaceuticals Contract Manufacturing Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Biopharmaceuticals Contract Manufacturing Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments
  • SwiftPharma and PlantForm Corporation target blockbuster cancer drug with new contract manufacturing agreement for plant-made biosimilars

    SwiftPharma joined forces with Canadian biopharmaceutical innovator PlantForm Corporation through a pivotal contract manufacturing arrangement. This collaboration is poised to revolutionize the production of antibodies and proteins by leveraging SwiftPharma's advanced manufacturing capabilities to synthesize biosimilar pembrolizumab, utilizing PlantForm's cutting-edge proprietary technology. [Published On: 2023-11-13]

  • Samsung Biologics Expands Strategic Manufacturing Agreement with Bristol Myers Squibb

    Samsung Biologics solidified its strategic alliance with global biopharma giant Bristol Myers Squibb through a newly announced agreement for the large-scale production of an antibody cancer drug substance. Under this collaboration, Samsung Biologics utilizes its state-of-the-art biomanufacturing facility, Plant 4, situated in Songdo, South Korea, to manufacture the drug substance for Bristol Myers Squibb. [Published On: 2023-09-20]

  • Hikma and SK Biopharmaceuticals enter a strategic partnership

    Hikma Pharmaceuticals PLC entered into a significant strategic partnership and exclusive licensing deal with SK Biopharmaceuticals to grant Hikma exclusive rights to commercialize and manufacture SK Biopharmaceuticals' innovative product lineup, including the groundbreaking anti-seizure medication, carbamate, across 17 countries within the Middle East & North Africa (MENA) region. [Published On: 2023-08-18]

Key Company Profiles

The report delves into recent significant developments in the Biopharmaceuticals Contract Manufacturing Market, highlighting leading vendors and their innovative profiles. These include 3P Biopharmaceuticals, AbbVie, Inc., Aenova Group GmbH, AGC Biologics, Ajinomoto Co., Inc., Aurobindo Pharma Limited, Boehringer Ingelheim International GmbH, Cambrex Corporation, Catalent, Inc., Celonic AG, FUJIFILM Diosynth Biotechnologies, INCOG BioPharma Services, Inc., JRS PHARMA GmbH + Co. KG, KBI Biopharma Inc, Lonza AG, Merck KGaA, Pressure BioSciences, Inc. by Emergent Health Corp., ProBioGen AG, Rentschler Biopharma SE, Samsung Biologics, Thermo Fisher Scientific Inc., Toyobo Co., Ltd., and WuXi Biologics, Inc..

Market Segmentation & Coverage

This research report categorizes the Biopharmaceuticals Contract Manufacturing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Product
    • Biologics
      • Monoclonal Antibodies
      • Recombinant Proteins
      • Vaccines
    • Biosimilar
  • Source
    • Mammalian
    • Non-Mammalian
  • Services
    • Analytical & QC studies
    • Fill & Finish Operations
    • Packaging
    • Process Development
      • Downstream
      • Upstream
  • Scale of Operation
    • Clinical
    • Commercial
  • Therapeutic Applications
    • Cardiovascular Diseases
    • Infectious Disease
    • Neurology
    • Oncology
    • Ophthalmology
    • Respiratory Disorder

  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

  1. What is the market size and forecast of the Biopharmaceuticals Contract Manufacturing Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Biopharmaceuticals Contract Manufacturing Market?
  3. What are the technology trends and regulatory frameworks in the Biopharmaceuticals Contract Manufacturing Market?
  4. What is the market share of the leading vendors in the Biopharmaceuticals Contract Manufacturing Market?
  5. Which modes and strategic moves are suitable for entering the Biopharmaceuticals Contract Manufacturing Market?

Table of Contents
  1. Preface
  2. Research Methodology
  3. Executive Summary
  4. Market Overview
  5. Market Insights
  6. Biopharmaceuticals Contract Manufacturing Market, by Product
  7. Biopharmaceuticals Contract Manufacturing Market, by Source
  8. Biopharmaceuticals Contract Manufacturing Market, by Services
  9. Biopharmaceuticals Contract Manufacturing Market, by Scale of Operation
  10. Biopharmaceuticals Contract Manufacturing Market, by Therapeutic Applications
  11. Americas Biopharmaceuticals Contract Manufacturing Market
  12. Asia-Pacific Biopharmaceuticals Contract Manufacturing Market
  13. Europe, Middle East & Africa Biopharmaceuticals Contract Manufacturing Market
  14. Competitive Landscape
  15. Competitive Portfolio
  16. List of Figures [Total: 26]
  17. List of Tables [Total: 646]
  18. List of Companies Mentioned [Total: 23]
Frequently Asked Questions
  1. How big is the Biopharmaceuticals Contract Manufacturing Market?
    Ans. The Global Biopharmaceuticals Contract Manufacturing Market size was estimated at USD 18.27 billion in 2023 and expected to reach USD 19.16 billion in 2024.
  2. What is the Biopharmaceuticals Contract Manufacturing Market growth?
    Ans. The Global Biopharmaceuticals Contract Manufacturing Market to grow USD 25.95 billion by 2030, at a CAGR of 5.14%
  3. When do I get the report?
    Ans. Most reports are fulfilled immediately. In some cases, it could take up to 2 business days.
  4. In what format does this report get delivered to me?
    Ans. We will send you an email with login credentials to access the report. You will also be able to download the pdf and excel.
  5. How long has 360iResearch been around?
    Ans. We are approaching our 7th anniversary in 2024!
  6. What if I have a question about your reports?
    Ans. Call us, email us, or chat with us! We encourage your questions and feedback. We have a research concierge team available and included in every purchase to help our customers find the research they need-when they need it.
  7. Can I share this report with my team?
    Ans. Absolutely yes, with the purchase of additional user licenses.
  8. Can I use your research in my presentation?
    Ans. Absolutely yes, so long as the 360iResearch cited correctly.